Home » Newsletters » BioWorld

BioWorld

April 29, 1994

View Archived Issues

ISIS' ANTISENSE DRUG SHOWS PROMISE

VIAGENE, CHIRON START METASTATIC MELANOMA STUDY

OTHER NEWS TO NOTE

LIDAK TO REDEEM CLASS B WARRANTS

CHIRON, CYTOMED UNITE TO DEVELOP COMPLEMENT INHIBITORS

ERYTHROPOIETIN CUTS TRANSFUSIONS IN LOW BIRTH WEIGHT STUDY

ONCOGENE, HOECHST-ROUSSEL TEAM FOR ALZHEIMER'S RESEARCH

ALPHA 1, SCICLONE HIT HARD BY RESULTS

BIOTECH TAX BONANZA PROPOSED BY ESHOO, BLUTE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...